WallStreetZenWallStreetZen

NASDAQ: CDT
Conduit Pharmaceuticals Inc Stock Ownership - Who owns Conduit Pharmaceuticals?

Insider buying vs selling

Have Conduit Pharmaceuticals Inc insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CDT insiders and whales buy or sell their stock.

CDT Shareholders

What type of owners hold Conduit Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Andrew Regan62.62%45,593,799$155.47MInsider
Jack Kendrick Heilbron6.55%4,769,250$16.26MInsider
David Tapolczay2.75%2,003,324$6.83MInsider
Barclays PLC1.10%804,292$2.74MInstitution
Murphy Canyon Acquisition Sponsor LLC1.04%754,000$2.57MInsider
Shaolin Capital Management LLC0.85%616,950$2.10MInsider
Freda C. Lewishall0.71%516,987$1.76MInsider
Vanguard Group Inc0.32%236,257$805.64kInstitution
Geode Capital Management LLC0.19%139,640$476.17kInstitution
Blackrock Inc0.19%137,962$470.45kInstitution

1 of 2

CDT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CDT1.89%74.63%
QURE78.37%13.99%Net SellingNet Selling
RIGL60.76%15.75%Net SellingNet Selling
PRLD52.44%47.56%Net BuyingNet Selling
GLSI4.01%95.99%Net BuyingNet Buying

Conduit Pharmaceuticals Stock Ownership FAQ

Who owns Conduit Pharmaceuticals?

Conduit Pharmaceuticals (NASDAQ: CDT) is owned by 1.89% institutional shareholders, 74.63% Conduit Pharmaceuticals insiders, and 23.48% retail investors. Andrew Regan is the largest individual Conduit Pharmaceuticals shareholder, owning 45.59M shares representing 62.62% of the company. Andrew Regan's Conduit Pharmaceuticals shares are currently valued at $162.77M.

If you're new to stock investing, here's how to buy Conduit Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.